Tosyalı Merve, Demirçelik Yavuz, Bağ Özlem, Karaarslan Utku, Gökçe Şule, Koç Feyza
Department of Pediatrics, Faculty of Medicine, Ege University, Children's Hospital, 35100 Izmir, Turkey.
Department of Pediatrics, Izmir City Hospital, 35180 Izmir, Turkey.
Healthcare (Basel). 2024 May 18;12(10):1043. doi: 10.3390/healthcare12101043.
To evaluate using different iron preparations for iron deficiency and/or iron deficiency anemia prophylaxis in infants and their iron status. In this study, we retrospectively evaluated the electronic patient records of 651 healthy children aged 9 to 13 months who met the inclusion criteria and who were followed up in pediatric follow-up outpatient clinics between January 2023 and June 2023. A total of 651 children with a mean age of 11.2 ± 1.4 months, 54.7% of whom were boys, who met the inclusion criteria were included in the study; 56.5% of the children were using Fe + 3 salt and the others were using Fe + 2 salt, microencapsulated iron, or sucrosomial iron drops. After the fifth month of prophylaxis, when the effects of the iron preparations used on the mean laboratory values were evaluated, it was found that hemoglobin, serum iron, and ferritin levels were lower in sucrosomial iron and microencapsulated iron users compared to other preparations ( = 0.001). When statistically pairwise comparisons were made between the groups, hemoglobin and serum iron values were found to be lower in the group using sucrosomial iron compared to the groups using Fe + 2 and Fe + 3 salts ( < 0.0001). Hemoglobin and ferritin levels were higher in the group using Fe + 2 salt compared to both sucrosomial iron and microencapsulated iron groups ( < 0.0001). When the infants were evaluated according to iron status, it was found that 208 (31.9%) had iron deficiency. Iron deficiency was found to be less in infants of families who defined their economic status as rich and in infants who used iron regularly (-values 0.044 and 0.001, respectively). Iron deficiency/iron deficiency anemia was observed at a higher rate in the group using sucrosomial iron and microencapsulated iron prophylaxis ( = 0.001). To prevent iron deficiency, it is very important to use appropriate iron preparations for prophylaxis and to feed foods with high iron content. Although we found that families were willing to use different iron preparations other than iron salts for their infants, the results presented herein indicate that the rate of iron deficiency was lower in patients using iron salts. However, randomized controlled studies are needed to determine whether these preparations are effective in iron prophylaxis in infants.
评估使用不同铁制剂预防婴儿缺铁和/或缺铁性贫血及其铁状态。在本研究中，我们回顾性评估了651名年龄在9至13个月之间符合纳入标准且于2023年1月至2023年6月在儿科随访门诊接受随访的健康儿童的电子病历。共有651名平均年龄为11.2±1.4个月、其中54.7%为男孩且符合纳入标准的儿童被纳入研究；56.5%的儿童使用Fe + 3盐，其他儿童使用Fe + 2盐、微囊化铁或蔗糖铁滴剂。在预防第五个月时，评估所用铁制剂对平均实验室值的影响，发现与其他制剂相比，使用蔗糖铁和微囊化铁的儿童血红蛋白、血清铁和铁蛋白水平较低（ = 0.001）。在组间进行统计学两两比较时，发现使用蔗糖铁的组与使用Fe + 2和Fe + 3盐的组相比，血红蛋白和血清铁值较低（ < 0.0001）。使用Fe + 2盐的组与蔗糖铁组和微囊化铁组相比，血红蛋白和铁蛋白水平较高（ < 0.0001）。根据铁状态对婴儿进行评估时，发现208名（31.9%）有缺铁情况。发现经济状况定义为富裕家庭的婴儿和定期使用铁剂的婴儿缺铁情况较少（-值分别为0.044和0.001）。在使用蔗糖铁和微囊化铁预防的组中，缺铁/缺铁性贫血的发生率较高（ = 0.001）。为预防缺铁，使用合适的铁制剂进行预防并喂养高铁含量的食物非常重要。尽管我们发现家庭愿意为其婴儿使用铁盐以外的不同铁制剂，但本文给出的结果表明，使用铁盐的患者缺铁率较低。然而，需要进行随机对照研究以确定这些制剂对婴儿铁预防是否有效。
